Because both EGFR and PDGFR signal through MAP2K2 (MEK2), the latter of which is significantly activated in the recurrent tumors, pharmacological blockade of MAP2K2 activity may be an alternative approach for the treatment of recurrent HPV+ HNSCC. This evidence concerns the gene MAP2K2 and head and neck squamous cell carcinoma.